Please use this identifier to cite or link to this item: https://hdl.handle.net/11499/8052
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVatankulu, M.A.-
dc.contributor.authorBacaksiz, A.-
dc.contributor.authorSonmez, O.-
dc.contributor.authorAlihanoglu, Y.-
dc.contributor.authorKoc, F.-
dc.contributor.authorDemir, K.-
dc.contributor.authorGul, E.E.-
dc.date.accessioned2019-08-16T12:34:51Z-
dc.date.available2019-08-16T12:34:51Z-
dc.date.issued2013-
dc.identifier.issn1755-5914-
dc.identifier.urihttps://hdl.handle.net/11499/8052-
dc.identifier.urihttps://doi.org/10.1111/1755-5922.12006-
dc.description.abstractAims: The aim of this study was to investigate the effects of spironolactone on left ventricular (LV) remodeling in patients with preserved LV function following acute myocardial infarction (AMI). Methods and Results: Successfully revascularized patients (n = 186) with acute ST elevation MI (STEMI) were included in the study. Patients were randomly divided into three groups, each of which was administered a different dose of spironolactone (12.5, 25 mg, or none). Echocardiography was performed within the first 3 days and at 6 months after MI. Echocardiography control was performed on 160 patients at a 6-month follow-up. The median left ventricular ejection fraction (LVEF) increased significantly in all groups, but no significant difference was observed between groups (P = 0.13). At the end of the sixth month, the myocardial performance index (MPI) had improved in each of the three groups, but no significant difference was found between groups (F = 2.00, P = 0.15). The mean LV peak systolic velocities (Sm) increased only in the control group during the follow-up period, but there is no significant difference between groups (F = 1.79, P = 0.18). The left ventricular end-systolic volume index (LVESVI) and the left ventricular end-diastolic volume index (LVEDVI) did not change significantly compared with the basal values between groups (F = 0.05, P = 0.81 and F = 1.03, P = 0.31, respectively). Conclusion: In conclusion, spironolactone dosages of up to 25 mg do not augment optimal medical treatment for LV remodeling in patients with preserved cardiac functions after AMI. © 2012 John Wiley & Sons Ltd.en_US
dc.language.isoenen_US
dc.relation.ispartofCardiovascular Therapeuticsen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAldosteroneen_US
dc.subjectMyocardial infarctionen_US
dc.subjectPreserved ejection fractionen_US
dc.subjectRemodelingen_US
dc.subjectSpironolactoneen_US
dc.subjectacetylsalicylic aciden_US
dc.subjectbisoprololen_US
dc.subjectcarvedilolen_US
dc.subjectfosinoprilen_US
dc.subjectmetoprololen_US
dc.subjectperindoprilen_US
dc.subjectramiprilen_US
dc.subjectspironolactoneen_US
dc.subjectvalsartanen_US
dc.subjectacute heart infarctionen_US
dc.subjectadulten_US
dc.subjectarticleen_US
dc.subjectcontrolled studyen_US
dc.subjectechocardiographyen_US
dc.subjectfemaleen_US
dc.subjectfollow upen_US
dc.subjectgynecomastiaen_US
dc.subjectheart left ventricle ejection fractionen_US
dc.subjectheart left ventricle enddiastolic volumeen_US
dc.subjectheart left ventricle endsystolic volumeen_US
dc.subjectheart left ventricle functionen_US
dc.subjectheart performanceen_US
dc.subjectheart ventricle remodelingen_US
dc.subjecthumanen_US
dc.subjecthyperkalemiaen_US
dc.subjecthypotensionen_US
dc.subjectmajor clinical studyen_US
dc.subjectmaleen_US
dc.subjectpriority journalen_US
dc.subjectrandomized controlled trialen_US
dc.subjectST segment elevation myocardial infarctionen_US
dc.subjectAdulten_US
dc.subjectAgeden_US
dc.subjectAnalysis of Varianceen_US
dc.subjectChi-Square Distributionen_US
dc.subjectDose-Response Relationship, Drugen_US
dc.subjectEchocardiography, Doppleren_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectMaleen_US
dc.subjectMiddle Ageden_US
dc.subjectMineralocorticoid Receptor Antagonistsen_US
dc.subjectMyocardial Contractionen_US
dc.subjectMyocardial Infarctionen_US
dc.subjectProspective Studiesen_US
dc.subjectStroke Volumeen_US
dc.subjectTime Factorsen_US
dc.subjectTreatment Outcomeen_US
dc.subjectTurkeyen_US
dc.subjectVentricular Function, Leften_US
dc.subjectVentricular Remodelingen_US
dc.titleDoes spironolactone have a dose-dependent effect on left ventricular remodeling in patients with preserved left ventricular function after an acute myocardial infarction?en_US
dc.typeArticleen_US
dc.identifier.volume31en_US
dc.identifier.issue4en_US
dc.identifier.startpage224
dc.identifier.startpage224en_US
dc.identifier.endpage229en_US
dc.identifier.doi10.1111/1755-5922.12006-
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.identifier.pmid22963506en_US
dc.identifier.scopus2-s2.0-84880666917en_US
dc.identifier.wosWOS:000321981400009en_US
dc.identifier.scopusqualityQ1-
dc.ownerPamukkale University-
item.languageiso639-1en-
item.openairetypeArticle-
item.grantfulltextopen-
item.cerifentitytypePublications-
item.fulltextWith Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Collections:PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection
Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection
Tıp Fakültesi Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection
Files in This Item:
File SizeFormat 
1755-5922.12006.pdf105.2 kBAdobe PDFView/Open
Show simple item record



CORE Recommender

SCOPUSTM   
Citations

12
checked on Jun 29, 2024

WEB OF SCIENCETM
Citations

11
checked on Jul 17, 2024

Page view(s)

20
checked on May 27, 2024

Download(s)

20
checked on May 27, 2024

Google ScholarTM

Check




Altmetric


Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.